Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders

 Tryp Therapeutics announced today that it has received correspondence from the U.S. Food and Drug Administration related to the Company’s Investigational New Drug application for a clinical study in overeating disorders.

Category Press Release

Companies Featured

Tryp Therapeutics
Tryp Therapeutics is a clinical stage drug development company developing psilocybin products for various diseases/disorders including fibromyalgia.